CYP24A1 as a potential target for cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 97-108

  Sakaki, Toshiyuki ^a   Yasuda, Kaori ^a   Kittaka, Atsushi ^b   Yamamoto, Keiko ^c   Chen, Tai C ^d  

^a TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapy; CYP24A1; Vitamin D analogs

Indexed keywords

ADRENODOXIN; CALCITRIOL; COLECALCIFEROL; COMPLEMENTARY DNA; CYTOCHROME; CYTOCHROME P450 24A1; CYTOCHROME P450 24A1 INHIBITOR; CYTOCHROME P450 INHIBITOR; ELDECALCITOL; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; MART 10; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; BIOSYNTHESIS; CANCER THERAPY; CELL FREE SYSTEM; DNA MICROARRAY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; HYDROXYLATION; METABOLITE; MOLECULAR CLONING; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; OXIDATIVE COUPLING; PROTEIN EXPRESSION; RESPIRATORY CHAIN; VITAMIN D METABOLISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHOLECALCIFEROL; ENZYME INHIBITORS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN CONFORMATION; STEROID HYDROXYLASES;

EID: 84899416915     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990307     Document Type: Article

References (120)

1. Osborn, J.L.; Schwartz, G.G.; Smith, D.C.; Bahnson, R.; Day, R.; Trump, D.L. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1995, 1(5), 195-198.
2. Gross, C.; Stamey, T.; Hancock, S.; Feldman, D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol., 1998, 159(6), 2035-2039; discussion 2039-2040.
3. Binderup, L.; Latini, S.; Binderup, E.; Bretting, C.; Calverley, M.; Hansen, K. 20-epi-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol., 1991, 42(8), 1569-1575.
4. Bishop, J.E.; Collins, E.D.; Okamura, W.H.; Norman, A.W. Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs. J. Bone Miner. Res., 1994, 9(8), 1277-1288.
5. Bouillon, R.; Okamura, W.H.; Norman, A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev., 1995, 16(2), 200-257.
6. Yamada, S.; Shimizu, M.; Yamamoto, K. Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med. Res. Rev., 2003, 23(1), 89-115.
7. Masuda, S.; Jones, G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., 2006, 5(4), 797-808.
8. Liu, G.; Oettel, K.; Ripple, G.; Staab, M.J.; Horvath, D.; Alberti, D.; Arzoomanian, R.; Marnocha, R.; Bruskewitz, R.; Mazess, R.; Bishop, C.; Bhattacharya, A.; Bailey, H.; Wilding, G. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res., 2002, 8(9), 2820-2827.
9. Lin, R.; Nagai, Y.; Sladek, R.; Bastien, Y.; Ho, J.; Petrecca, K.; Sotiropoulou, G.; Diamandis, E.P.; Hudson, T.J.; White, J.H. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol., 2002, 16(6), 1243-1256.
10. Evans, T.R.; Colston, K.W.; Lofts, F.J.; Cunningham, D.; Anthoney, D.A.; Gogas, H.; De Bono, J.S.; Hamberg, K.J.; Skov, T.; Mansi, J.L. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer, 2002, 86(5), 680-685.
11. Liu, G.; Wilding, G.; Staab, M.J.; Horvath, D.; Miller, K.; Dresen, A.; Alberti, D.; Arzoomanian, R.; Chappell, R.; Bailey, H.H. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res., 2003, 9(11), 4077-4083.
12. Schwartz, G.G.; Hall, M.C.; Stindt, D.; Patton, S.; Lovato, J.; Torti, F.M. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res., 2005, 11(24 Pt 1), 8680-8685.
13. Kittaka, A.; Suhara, Y.; Takayanagi, H.; Fujishima, T.; Kurihara, M.; Takayama, H. A concise and efficient route to 2alpha-(omega-hydroxyalkoxy)-1alpha,25-dihydroxyvi tam in D3: Remarkably high affinity to vitamin D receptor. Org. Lett., 2000, 2(17), 2619-2622.
14. Suhara, Y.; Nihei, K.I.; Tanigawa, H.; Fujishima, T.; Konno, K.; Nakagawa, K.; Okano, T.; Takayama, H. Syntheses and biological evaluation of novel 2alpha-substituted 1alpha,25-dihydroxyvitamin D3 analogues. Bioorg. Med. Chem. Lett., 2000, 10(10), 1129-1132.
15. Suhara, Y.; Nihei, K.I.; Kurihara, M.; Kittaka, A.; Yamaguchi, K.; Fujishima, T.; Konno, K.; Miyata, N.; Takayama, H. Efficient and versatile synthesis of novel 2alpha-substituted 1alpha,25-dihydroxyvitamin D(3) analogues and their docking to vitamin D receptors. J. Org. Chem., 2001, 66(26), 8760-8771.
16. Saito, N.; Suhara, Y.; Kurihara, M.; Fujishima, T.; Honzawa, S.; Takayanagi, H.; Kozono, T.; Matsumoto, M.; Ohmori, M.; Miyata, N.; Takayama, H.; Kittaka, A. Design and efficient synthesis of 2 alpha-(omega-hydroxyalkoxy)-1 alpha,25-dihydroxyvitamin D3 Analogues, including 2-epi-ED-71 and their 20-epimers with HL-60 cell differentiation activity. J. Org. Chem., 2004, 69(22), 7463-7471.
17. Takahashi, E.; Nakagawa, K.; Suhara, Y.; Kittaka, A.; Nihei, K.; Konno, K.; Takayama, H.; Ozono, K.; Okano, T. Biological activities of 2alpha-substituted analogues of 1alpha,25-dihydroxyvitamin D3 in transcriptional regulation and human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Biol. Pharm. Bull., 2006, 29(11), 2246-2250.
18. Kittaka, A. Structural refinement of seco-steroidal skeleton and the biological activity through nuclear receptors. Yakugaku Zasshi, 2008, 128(9), 1235-1250.
19. Ono, K.; Yoshida, A.; Saito, N.; Fujishima, T.; Honzawa, S.; Suhara, Y.; Kishimoto, S.; Sugiura, T.; Waku, K.; Takayama, H.; Kittaka, A. Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. J. Org. Chem., 2003, 68(19), 7407-7415.
20. Arai, M.A.; Takeyama, K.; Ito, S.; Kato, S.; Chen, T.C.; Kittaka, A. High-throughput system for analyzing ligand-induced cofactor recruitment by vitamin D receptor. Bioconjug. Chem., 2007, 18(3), 614-620.
21. Chen, T.C.; Persons, K.S.; Zheng, S.; Mathieu, J.; Holick, M.F.; Lee, Y.F.; Bao, B.; Arai, M.A.; Kittaka, A. Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer. J. Steroid Biochem. Mol. Biol., 2007, 103(3-5), 717-720.
22. Flanagan, J.N.; Zheng, S.; Chiang, K.C.; Kittaka, A.; Sakaki, T.; Nakabayashi, S.; Zhao, X.; Spanjaard, R.A.; Persons, K.S.; Mathieu, J.S.; Holick, M.F.; Chen, T.C. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res., 2009, 29(9), 3547-3553.
23. Chen, T.C.; Kittaka, A. Novel vitamin d analogs for prostate cancer therapy. ISRN Urol., 2011, 2011, 301490.
24. Chiang, K.C.; Yeh, C.N.; Chen, S.C.; Shen, S.C.; Hsu, J.T.; Yeh, T.S.; Pang, J.H.; Su, L.J.; Takano, M.; Kittaka, A.; Juang, H.H.; Chen, T.C. MART-10, a new generation of vitamin d analog, is more potent than 1alpha,25-dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells. Evid. Based Complement. Alternat. Med., 2012, 2012, 310872.
25. Iglesias-Gato, D.; Zheng, S.; Flanagan, J.N.; Jiang, L.; Kittaka, A.; Sakaki, T.; Yamamoto, K.; Itoh, T.; Lebrasseur, N.K.; Norstedt, G.; Chen, T.C. Substitution at carbon 2 of 19-nor-1alpha,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J. Steroid Biochem. Mol. Biol., 2011, 127(3-5), 269-275.
26. Ohyama, Y.; Ozono, K.; Uchida, M.; Shinki, T.; Kato, S.; Suda, T.; Yamamoto, O.; Noshiro, M.; Kato, Y. Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J. Biol. Chem., 1994, 269(14), 10545-10550.
27. Akiyoshi-Shibata, M.; Sakaki, T.; Ohyama, Y.; Noshiro, M.; Okuda, K.; Yabusaki, Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur. J. Biochem., 1994, 224(2), 335-343.
28. Sakaki, T.; Sawada, N.; Nonaka, Y.; Ohyama, Y.; Inouye, K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem., 1999, 262(1), 43-48.
29. Norman, A.W.; Myrtle, J.F.; Midgett, R.J.; Nowicki, H.G.; Williams, V.; Popjak, G. 1,25-dihydroxycholecalciferol: Identification of the proposed active form of vitamin D3 in the intestine. Science, 1971, 173(3991), 51-54.
30. Holick, M.F.; Schnoes, H.K.; DeLuca, H.F. Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc. Natl. Acad. Sci. USA, 1971, 68(4), 803-804.
31. Lawson, D.E.; Fraser, D.R.; Kodicek, E.; Morris, H.R.; Williams, D.H. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature, 1971, 230(5291), 228-230.
32. Boyle, I.T.; Gray, R.W.; DeLuca, H.F. Regulation by calcium of in vivo synthesis of 1,25-dihydroxycholecalciferol and 21,25-dihydroxycholecalciferol. Proc. Natl. Acad. Sci USA, 1971, 68(9), 2131-2134.
33. Bikle, D.D.; Nemanic, M.K.; Gee, E.; Elias, P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J. Clin. Invest., 1986, 78(2), 557-566.
34. Jones, G.; Strugnell, S.A.; DeLuca, H.F. Current understanding of the molecular actions of vitamin D. Physiol. Rev., 1998, 78(4), 1193-1231.
35. Cross, H.S.; Peterlik, M.; Reddy, G.S.; Schuster, I. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J. Steroid Biochem. Mol. Biol., 1997, 62(1), 21-28.
36. Friedrich, M.; Diesing, D.; Cordes, T.; Fischer, D.; Becker, S.; Chen, T.C.; Flanagan, J.N.; Tangpricha, V.; Gherson, I.; Holick, M.F.; Reichrath, J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res., 2006, 26(4A), 2615-2620.
37. Kemmis, C.M.; Salvador, S.M.; Smith, K.M.; Welsh, J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J. Nutr., 2006, 136(4), 887-892.
38. Schwartz, G.G.; Whitlatch, L.W.; Chen, T.C.; Lokeshwar, B.L.; Holick, M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev., 1998, 7(5), 391-395.
39. Hewison, M.; Zehnder, D.; Bland, R.; Stewart, P.M. 1alpha-hydroxylase and the action of vitamin D. J. Mol. Endocrinol., 2000, 25(2), 141-148.
40. Young, M.V.; Schwartz, G.G.; Wang, L.; Jamieson, D.P.; Whitlatch, L.W.; Flanagan, J.N.; Lokeshwar, B.L.; Holick, M.F.; Chen, T.C. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis, 2004, 25(6), 967-971.
41. Akeno, N.; Saikatsu, S.; Kawane, T.; Horiuchi, N. Mouse vitamin D-24-hydroxylase: Molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology, 1997, 138(6), 2233-2240.
42. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta, 2011, 1814(1), 186-199.
43. Beckman, M.J.; Tadikonda, P.; Werner, E.; Prahl, J.; Yamada, S.; DeLuca, H.F. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry, 1996, 35(25), 8465-8472.
44. Sakaki, T.; Kagawa, N.; Yamamoto, K.; Inouye, K. Metabolism of vitamin D3 by cytochromes P450. Front. Biosci., 2005, 10, 119-134.
45. Stumpf, W.E.; Sar, M.; Reid, F.A.; Tanaka, Y.; DeLuca, H.F. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science, 1979, 206(4423), 1188-1190.
46. Colston, K.; Hirt, M.; Feldman, D. Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology, 1980, 107(6), 1916-1922.
47. Suda, T.; Abe, E., Eds. Induction of differentiation of human myeloid leukemia cells by 1,25-dihydroxyvitamin D3 Walter de Gruyter: New York, 1982.
48. Abe, E.; Miyaura, C.; Sakagami, H.; Takeda, M.; Konno, K.; Yamazaki, T.; Yoshiki, S.; Suda, T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA, 1981, 78(8), 4990-4994.
49. Tanaka, H.; Abe, E.; Miyaura, C.; Kuribayashi, T.; Konno, K.; Nishii, Y.; Suda, T. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem. J., 1982, 204(3), 713-719.
50. Skowronski, R.J.; Peehl, D.M.; Feldman, D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 1993, 132(5), 1952-1960.
51. Chen, T.C.; Holick, M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab., 2003, 14(9), 423-430.
52. Holick, M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr., 2004, 80(6 Suppl), 1678S-1688S.
53. Simboli-Campbell, M.; Narvaez, C.J.; van Weelden, K.; Tenniswood, M.; Welsh, J. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat., 1997, 42(1), 31-41.
54. Inoue, T.; Kamiyama, J.; Sakai, T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J. Biol. Chem., 1999, 274(45), 32309-32317.
55. Hager, G.; Formanek, M.; Gedlicka, C.; Thurnher, D.; Knerer, B.; Kornfehl, J. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol., 2001, 121(1), 103-109.
56. Wu, G.; Fan, R.S.; Li, W.; Ko, T.C.; Brattain, M.G. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene, 1997, 15(13), 1555-1563.
57. Cordero, J.B.; Cozzolino, M.; Lu, Y.; Vidal, M.; Slatopolsky, E.; Stahl, P.D.; Barbieri, M.A.; Dusso, A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem., 2002, 277(41), 38965-38971.
58. Kawata, H.; Kamiakito, T.; Takayashiki, N.; Tanaka, A. Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8. J. Cell Physiol., 2006, 207(3), 793-799.
59. Wu, Y.; Craig, T.A.; Lutz, W.H.; Kumar, R. Identification of 1 alpha,25-dihydroxyvitamin D3 response elements in the human transforming growth factor beta 2 gene. Biochemistry, 1999, 38(9), 2654-2660.
60. Xie, S.P.; Pirianov, G.; Colston, K.W. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur. J. Cancer, 1999, 35(12), 1717-1723.
61. Hmama, Z.; Nandan, D.; Sly, L.; Knutson, K.L.; Herrera-Velit, P.; Reiner, N.E. 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J. Exp. Med., 1999, 190(11), 1583-1594.
62. Penna, G.; Adorini, L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol., 2000, 164(5), 2405-2411.
63. Ylikomi, T.; Laaksi, I.; Lou, Y.R.; Martikainen, P.; Miettinen, S.; Pennanen, P.; Purmonen, S.; Syvala, H.; Vienonen, A.; Tuohimaa, P. Antiproliferative action of vitamin D. Vitam. Horm., 2002, 64, 357-406.
64. Chaudhry, M.; Sundaram, S.; Gennings, C.; Carter, H.; Gewirtz, D.A. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother. Pharmacol., 2001, 47(5), 429-436.
65. Posner, G.H.; Crawford, K.R.; Peleg, S.; Welsh, J.E.; Romu, S.; Gewirtz, D.A.; Gupta, M.S.; Dolan, P.; Kensler, T.W. A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): Chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg. Med. Chem., 2001, 9(9), 2365-2371.
66. Sundaram, S.; Gewirtz, D.A. The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation. Radiat. Res., 1999, 152(5), 479-486.
67. Sundaram, S.; Sea, A.; Feldman, S.; Strawbridge, R.; Hoopes, P.J.; Demidenko, E.; Binderup, L.; Gewirtz, D.A. The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res., 2003, 9(6), 2350-2356.
68. Chung, I.; Wong, M.K.; Flynn, G.; Yu, W.D.; Johnson, C.S.; Trump, D.L. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res., 2006, 66(17), 8565-8573.
69. Merke, J.; Milde, P.; Lewicka, S.; Hugel, U.; Klaus, G.; Mangelsdorf, D.J.; Haussler, M.R.; Rauterberg, E.W.; Ritz, E. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest., 1989, 83(6), 1903-1915.
70. Iseki, K.; Tatsuta, M.; Uehara, H.; Iishi, H.; Yano, H.; Sakai, N.; Ishiguro, S. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer, 1999, 81(5), 730-733.
71. Getzenberg, R.H.; Light, B.W.; Lapco, P.E.; Konety, B.R.; Nangia, A.K.; Acierno, J.S.; Dhir, R.; Shurin, Z.; Day, R.S.; Trump, D.L.; Johnson, C.S. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology, 1997, 50(6), 999-1006.
72. Nakagawa, K.; Kawaura, A.; Kato, S.; Takeda, E.; Okano, T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis, 2005, 26(2), 429-440.
73. Ohyama, Y.; Noshiro, M.; Okuda, K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett., 1991, 278(2), 195-198.
74. Ohyama, Y.; Hayashi, S.; Okuda, K. Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS Lett., 1989, 255(2), 405-408.
75. Urushino, N.; Nakabayashi, S.; Arai, M.A.; Kittaka, A.; Chen, T.C.; Yamamoto, K.; Hayashi, K.; Kato, S.; Ohta, M.; Kamakura, M.; Ikushiro, S.; Sakaki, T. Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1. Drug Metab. Dispos., 2007, 35(9), 1482-1488.
76. Abe, D.; Sakaki, T.; Kusudo, T.; Kittaka, A.; Saito, N.; Suhara, Y.; Fujishima, T.; Takayama, H.; Hamamoto, H.; Kamakura, M.; Ohta, M.; Inouye, K. Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab. Dispos., 2005, 33(6), 778-784.
77. Kusudo, T.; Sakaki, T.; Abe, D.; Fujishima, T.; Kittaka, A.; Takayama, H.; Hatakeyama, S.; Ohta, M.; Inouye, K. Metabolism of A-ring diastereomers of 1alpha,25-dihydroxyvitamin D3 by CYP24A1. Biochem. Biophys. Res. Commun., 2004, 321(4), 774-782.
78. Kasai, N.; Sakaki, T.; Shinkyo, R.; Ikushiro, S.; Iyanagi, T.; Ohta, M.; Inouye, K. Metabolism of 26,26,26,27,27,27-F6-1 alpha, 23S,25-trihydroxyvitamin D3 by human UDP-glucuronosyltrans-ferase 1A3. Drug Metab. Dispos., 2005, 33(1), 102-107.
79. Saito, N.; Suhara, Y.; Abe, D.; Kusudo, T.; Ohta, M.; Yasuda, K.; Sakaki, T.; Honzawa, S.; Fujishima, T.; Kittaka, A. Synthesis of 2alpha-propoxy-1alpha,25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. Bioorg. Med. Chem., 2009, 17(13), 4296-4301.
80. Sawada, D.; Tsukuda, Y.; Yasuda, K.; Sakaki, T.; Saito, H.; Takagi, K.; takenouchi, K.; Chen, T.; Reddy, S.; Kittaka, A. Synthesis of 1a,4a,25- and 1a,4p,25-Trihydroxyvitamin D3 and their metabolism by human CYP24A1 and human liver microsomal fraction. Chem. Pharm. Bull, 2012, 60(10), 1-4.
81. Sakaki, T.; Sawada, N.; Komai, K.; Shiozawa, S.; Yamada, S.; Yamamoto, K.; Ohyama, Y.; Inouye, K. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem., 2000, 267(20), 6158-6165.
82. Sawada, N.; Kusudo, T.; Sakaki, T.; Hatakeyama, S.; Hanada, M.; Abe, D.; Kamao, M.; Okano, T.; Ohta, M.; Inouye, K. Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1. Biochemistry, 2004, 43(15), 4530-4537.
83. Makin, G.; Lohnes, D.; Byford, V.; Ray, R.; Jones, G. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem. J., 1989, 262(1), 173-180.
84. Ohyama, Y.; Ozono, K.; Uchida, M.; Yoshimura, M.; Shinki, T.; Suda, T.; Yamamoto, O. Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J. Biol. Chem., 1996, 271(48), 30381-30385.
85. Hamamoto, H.; Kusudo, T.; Urushino, N.; Masuno, H.; Yamamoto, K.; Yamada, S.; Kamakura, M.; Ohta, M.; Inouye, K.; Sakaki, T. Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: Amino acid residues responsible for species-based difference of CYP24A1 between humans and rats. Mol. Pharmacol, 2006, 70(1), 120-128.
86. Annalora, A.J.; Goodin, D.B.; Hong, W.X.; Zhang, Q.; Johnson, E.F.; Stout, CD. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J. Mol. Biol., 2010, 396(2), 441-451.
87. Meyer, M.B.; Zella, L.A.; Nerenz, R.D.; Pike, J.W. Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D3 in mouse kidney and intestine in vivo. J. Biol. Chem., 2007, 282(31), 22344-22352.
88. Ohyama, Y.; Kusada, T.; Yamasaki, T.; Ide, H. Extensive methylation of CpG island of CYP24 gene in osteoblastic ROS17/2.8 cells. Nucleic Acids Res. Suppl, 2002(2), 249-250.
89. Chung, I.; Karpf, A.R.; Muindi, J.R.; Conroy, J.M.; Nowak, N.J.; Johnson, C.S.; Trump, D.L. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J. Biol. Chem., 2007, 282(12), 8704-8714.
90. Makishima, M.; Lu, T.T.; Xie, W.; Whitfield, G.K.; Domoto, H.; Evans, R.M.; Haussler, M.R.; Mangelsdorf, D.J. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002, 296(5571), 1313-1316.
91. Zou, A.; Elgort, M.G.; Allegretto, E.A. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J. Biol. Chem., 1997, 272(30), 19027-19034.
92. Konno, Y.; Kodama, S.; Moore, R.; Kamiya, N.; Negishi, M. Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Mol. Pharmacol, 2009, 75(2), 265-271.
93. Shankar, K.; Liu, X.; Singhal, R.; Chen, J.R.; Nagarajan, S.; Badger, T.M.; Ronis, M.J. Chronic ethanol consumption leads to disruption of vitamin D3 homeostasis associated with induction of renal 1,25 dihydroxyvitamin D3-24-hydroxylase (CYP24A1). Endocrinology, 2008, 149(4), 1748-1756.
94. Matsunawa, M.; Amano, Y.; Endo, K.; Uno, S.; Sakaki, T.; Yamada, S.; Makishima, M. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicol. Sci., 2009, 109(1), 50-58.
95. Chiang, K.C.; Chen, T.C. The Anti-cancer Actions of Vitamin D. Anticancer Agents Med. Chem., 2013, 13(1), 126-139.
96. Luo, W.; Karpf, A.R.; Deeb, K.K.; Muindi, J.R.; Morrison, C.D.; Johnson, C.S.; Trump, D.L. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res., 2010, 70(14), 5953-5962.
97. Deeb, K.K.; Luo, W.; Karpf, A.R.; Omilian, A.R.; Bshara, W.; Tian, L.; Tangrea, M.A.; Morrison, C.D.; Johnson, C.S.; Trump, D.L. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics, 2011, 6(8), 994-1000.
98. Albertson, D.G.; Ylstra, B.; Segraves, R.; Collins, C.; Dairkee, S.H.; Kowbel, D.; Kuo, W.L.; Gray, J.W.; Pinkel, D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet., 2000, 25(2), 144-146.
99. Wong, M.P.; Fung, L.F.; Wang, E.; Chow, W.S.; Chiu, S.W.; Lam, W.K.; Ho, K.K.; Ma, E.S.; Wan, T.S.; Chung, L.P. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer, 2003, 97(5), 1263-1270.
100. Hidaka, S.; Yasutake, T.; Takeshita, H.; Kondo, M.; Tsuji, T.; Nanashima, A.; Sawai, T.; Yamaguchi, H.; Nakagoe, T.; Ayabe, H.; Tagawa, Y. Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin. Cancer Res., 2000, 6(7), 2712-2717.
101. Rygiel, A.M.; Milano, F.; Ten Kate, F.J.; Schaap, A.; Wang, K.K.; Peppelenbosch, M.P.; Bergman, J.J.; Krishnadath, K.K. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev., 2008, 17(6), 1380-1385.
102. Meijer, G.A.; Hermsen, M.A.; Baak, J.P.; van Diest, P.J.; Meuwissen, S.G.; Belien, J.A.; Hoovers, J.M.; Joenje, H.; Snijders, P.J.; Walboomers, J.M. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J. Clin. Pathol., 1998, 51(12), 901-909.
103. Friedrich, M.; Rafi, L.; Mitschele, T.; Tilgen, W.; Schmidt, W.; Reichrath, J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res., 2003, 164, 239-246.
104. Parise, R.A.; Egorin, M.J.; Kanterewicz, B.; Taimi, M.; Petkovich, M.; Lew, A.M.; Chuang, S.S.; Nichols, M.; El-Hefnawy, T.; Hershberger, P.A. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer, 2006, 119(8), 1819-1828.
105. Horvath, H.C.; Lakatos, P.; Kosa, J.P.; Bacsi, K.; Borka, K.; Bises, G.; Nittke, T.; Hershberger, P.A.; Speer, G.; Kallay, E. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J. Histochem Cytochem., 2010, 58(3), 277-285.
106. Komagata, S.; Nakajima, M.; Takagi, S.; Mohri, T.; Taniya, T.; Yokoi, T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol., 2009, 76(4), 702-709.
107. Schuster, I.; Egger, H.; Reddy, G.S.; Vorisek, G. Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism. Rec. Results Cancer Res., 2003, 164, 169-188.
108. Posner, G.H.; Crawford, K.R.; Yang, H.W.; Kahraman, M.; Jeon, H.B.; Li, H.; Lee, J.K.; Suh, B.C.; Hatcher, M.A.; Labonte, T.; Usera, A.; Dolan, P.M.; Kensler, T.W.; Peleg, S.; Jones, G.; Zhang, A.; Korczak, B.; Saha, U.; Chuang, S.S. Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1alpha,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol., 2004, 89-90(1-5), 5-12.
109. Kahraman, M.; Sinishtaj, S.; Dolan, P.M.; Kensler, T.W.; Peleg, S.; Saha, U.; Chuang, S.S.; Bernstein, G.; Korczak, B.; Posner, G.H. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J. Med. Chem., 2004, 47(27), 6854-6863.
110. Strushkevich, N.; Usanov, S.A.; Plotnikov, A.N.; Jones, G.; Park, H.W. Structural analysis of CYP2R1 in complex with vitamin D3. J. Mol. Biol., 2008, 380(1), 95-106.
111. Chiellini, G.; Rapposelli, S.; Zhu, J.; Massarelli, I.; Saraceno, M.; Bianucci, A.M.; Plum, L.A.; Clagett-Dame, M.; DeLuca, H.F. Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase. Steroids, 2012, 77(3), 212-223.
112. Koenig, K.; Schlichting, I. Cytochromes P450- Structural basis for binding and catalysis. Met. Ions Life Sci., 2007, 3, 235-265.
113. Wang, Z.; Lin, Y.S.; Zheng, X.E.; Senn, T.; Hashizume, T.; Scian, M.; Dickmann, L.J.; Nelson, S.D.; Baillie, T.A.; Hebert, M.F.; Blough, D.; Davis, C.L.; Thummel, K.E. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol. Pharmacol., 2012, 81(4), 498-509.
114. Xu, Y.; Hashizume, T.; Shuhart, M.C.; Davis, C.L.; Nelson, W.L.; Sakaki, T.; Kalhorn, T.F.; Watkins, P.B.; Schuetz, E.G.; Thummel, K.E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): Implications for drug-induced osteomalacia. Mol. Pharmacol., 2006, 69(1), 56-65.
115. Yasuda, K.; Ikushiro, S.; Kamakura, M.; Takano, M.; Saito, N.; Kittaka, A.; Chen, T.C.; Ohta, M.; Sakaki, T. Human cytochrome P450-dependent differential metabolism among three 2alpha-substituted-1alpha,25-dihydroxyvitamin D(3) analogs. J. Steroid Biochem. Mol. Biol., 2013, 133, 84-92.
116. Farhan, H.; Wahala, K.; Adlercreutz, H.; Cross, H.S. Isoflavonoids inhibit catabolism of vitamin D in prostate cancer cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 777(1-2), 261-268.
117. Kallay, E.; Adlercreutz, H.; Farhan, H.; Lechner, D.; Bajna, E.; Gerdenitsch, W.; Campbell, M.; Cross, H.S. Phytoestrogens regulate vitamin D metabolism in the mouse colon: Relevance for colon tumor prevention and therapy. J. Nutr., 2002, 132(11 Suppl), 3490S-3493S.
118. Rao, A.; Woodruff, R.D.; Wade, W.N.; Kute, T.E.; Cramer, S.D. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J. Nutr., 2002, 132(10), 3191-3194.
119. Farhan, H.; Wahala, K.; Cross, H.S. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol., 2003, 84(4), 423-429.
120. Swami, S.; Krishnan, A.V.; Peehl, D.M.; Feldman, D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol. Cell Endocrinol., 2005, 241(1-2), 49-61.